CN Patent

CN114181195A — 一种化合物的结晶多晶型物

Assigned to Global Blood Therapeutics Inc · Expires 2022-03-15 · 4y expired

What this patent protects

本文披露了2‑羟基‑6‑((2‑(1‑异丙基‑1H‑吡唑‑5‑基)吡啶‑3‑基)甲氧基)苯甲醛(或化合物1)的结晶游离碱非溶剂化物形式，如游离碱形式I、形式II和物质N。还披露了2‑羟基‑6‑((2‑(1‑异丙基‑1H‑吡唑‑5‑基)吡啶‑3‑基)甲氧基)苯甲醛(或化合物1)的结晶游离碱溶剂化物。

USPTO Abstract

本文披露了2‑羟基‑6‑((2‑(1‑异丙基‑1H‑吡唑‑5‑基)吡啶‑3‑基)甲氧基)苯甲醛(或化合物1)的结晶游离碱非溶剂化物形式，如游离碱形式I、形式II和物质N。还披露了2‑羟基‑6‑((2‑(1‑异丙基‑1H‑吡唑‑5‑基)吡啶‑3‑基)甲氧基)苯甲醛(或化合物1)的结晶游离碱溶剂化物。

Drugs covered by this patent

Patent Metadata

Patent number
CN114181195A
Jurisdiction
CN
Classification
—
Expires
2022-03-15
Drug substance claim
No
Drug product claim
No
Assignee
Global Blood Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.